{"pmcid": 115849, "prompt_strategy": "fewshot", "model": "gpt-5.1", "extractions": [{"outcome": "Discontinuation due to lack of efficacy", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "intervention_events": 44.0, "comparator_events": 19.0, "outcome_type": "binary"}, {"outcome": "Patient global assessment of disease activity", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_mean": 56.07, "comparator_mean": 66.0, "outcome_type": "continuous"}, {"outcome": "investigator global assessment of disease activity", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_mean": 2.27, "comparator_mean": 2.7, "outcome_type": "continuous"}, {"outcome": "Tender joint count", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_mean": 25.58, "comparator_mean": 29.0, "outcome_type": "continuous"}, {"outcome": "Swollen joint count", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_mean": 17.57, "comparator_mean": 19.0, "outcome_type": "continuous"}, {"outcome": "Patient global assessment of pain", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_mean": 55.38, "comparator_mean": 65.0, "outcome_type": "continuous"}, {"outcome": "Health Assessment Questionnaire disability", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_mean": 1.8, "comparator_mean": 2.0, "outcome_type": "continuous"}, {"outcome": "Serum C-reactive protein", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "outcome_type": "continuous"}, {"outcome": "ACR20 responder criteria", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_events": 207.0, "comparator_events": 146.0, "outcome_type": "binary"}, {"outcome": "Discontinuation due to lack of efficacy", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_events": 44.0, "comparator_events": 90.0, "outcome_type": "binary"}, {"outcome": "Patient global assessment of disease activity", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_mean": 56.0, "comparator_mean": 66.0, "outcome_type": "continuous"}, {"outcome": "investigator global assessment of disease activity", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_mean": 2.19, "comparator_mean": 2.7, "outcome_type": "continuous"}, {"outcome": "Tender joint count", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_mean": 25.84, "comparator_mean": 29.0, "outcome_type": "continuous"}, {"outcome": "Swollen joint count", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_mean": 17.61, "comparator_mean": 19.0, "outcome_type": "continuous"}, {"outcome": "Patient global assessment of pain", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_mean": 54.54, "comparator_mean": 65.0, "outcome_type": "continuous"}, {"outcome": "Health Assessment Questionnaire disability", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_mean": 1.71, "comparator_mean": 2.0, "outcome_type": "continuous"}, {"outcome": "Serum C-reactive protein", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "outcome_type": "continuous"}, {"outcome": "ACR20 responder criteria", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_events": 104.0, "comparator_events": 146.0, "outcome_type": "binary"}, {"outcome": "Discontinuation due to lack of efficacy", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_events": 19.0, "comparator_events": 90.0, "outcome_type": "binary"}, {"outcome": "Patient global assessment of disease activity", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "intervention_mean": 56.07, "comparator_mean": 56.0, "outcome_type": "continuous"}, {"outcome": "investigator global assessment of disease activity", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "intervention_mean": 2.27, "comparator_mean": 2.19, "outcome_type": "continuous"}, {"outcome": "Tender joint count", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "intervention_mean": 25.58, "comparator_mean": 25.84, "outcome_type": "continuous"}, {"outcome": "Swollen joint count", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "intervention_mean": 17.57, "comparator_mean": 17.61, "outcome_type": "continuous"}, {"outcome": "Patient global assessment of pain", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "intervention_mean": 55.38, "comparator_mean": 54.54, "outcome_type": "continuous"}, {"outcome": "Health Assessment Questionnaire disability", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "intervention_mean": 1.8, "comparator_mean": 1.71, "outcome_type": "continuous"}, {"outcome": "Serum C-reactive protein", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "outcome_type": "continuous"}, {"outcome": "ACR20 responder criteria", "intervention": "etoricoxib 90 mg once daily", "comparator": "naproxen 500 mg twice daily", "intervention_group_size": 353.0, "comparator_group_size": 181.0, "intervention_events": 207.0, "comparator_events": 104.0, "outcome_type": "binary"}, {"outcome": "patients discontinued due to lack of efficacy", "intervention": "etoricoxib 90 mg once daily", "comparator": "placebo", "intervention_group_size": 353.0, "comparator_group_size": 357.0, "intervention_events": 44.0, "comparator_events": 90.0, "outcome_type": "binary"}, {"outcome": "patients discontinued due to lack of efficacy", "intervention": "naproxen 500 mg twice daily", "comparator": "placebo", "intervention_group_size": 181.0, "comparator_group_size": 357.0, "intervention_events": 19.0, "comparator_events": 90.0, "outcome_type": "binary"}], "errors": []}
